Thursday, December 20, 2012 1:59:41 PM
Wednesday 19 December 2012
Cancer Research UK Press Release
http://www.cancerresearchuk.org/cancer-info/news/archive/pressrelease/2012-12-19-lifetime-cancer-risk-for-men-to-climb-to-one-in-two?rss=true
A man's lifetime risk of developing cancer is set to reach one in two by 2027 according to new Cancer Research UK figures released today (Wednesday).
This prediction means that within 15 years 50 men out of every 100 are likely to be diagnosed with cancer at some point in their lifetime as opposed to 44 out of every 100 in 2010.
Women’s lifetime cancer risk is also increasing and is predicted to rise from 40 to 44 out of every 100 women by 2027.
Set against this is the fact that cancer survival has doubled in the last 40 years thanks to research developing better techniques to detect the disease and improved treatments to increase survival. So while the risk of being diagnosed with cancer is rising, the overall chance of surviving it is improving.
Age is the biggest risk factor for cancer and the increase in risk is largely due to more people living longer. As our lifespan increases more people will reach an age when they are more likely to be diagnosed with cancer.
These projections are released ahead of a new Cancer Research UK TV advertising campaign launching on Boxing Day that is designed to highlight that it is only through research that cancer will be beaten.
The cancers set to increase most in the next 15 years include prostate, bowel and melanoma.
Prostate cancer remains a continuing challenge. Cases of the disease are rising but it is not yet possible to distinguish which prostate cancers will be life-threatening and which won’t.
Professor Malcolm Mason, Cancer Research UK’s prostate cancer expert, said: “Prostate cancer needs research. We have many questions and research is key to providing answers about the disease. As our population ages, growing numbers of men will be diagnosed with the disease. Over the last 40 years prostate cancer incidence rates in Great Britain have tripled, and three-quarters of cases are diagnosed in men aged over 65 years.”
One example of where research may lead us is the earlier work from Cancer Research UK scientists that indicates a protein called MSMB may help identify men at greater risk of prostate cancer. The researchers showed that this protein seems more accurately linked to prostate cancer than the marker currently tested for – the prostate specific antigen (PSA).
Professor Mason added: “It’s men at higher risk of the disease who might benefit most from screening, and targeting screening to these men could be a better approach than screening all men. Further work is needed to prove if this test could be useful but it’s only through continued research that we’ll be able to offer improved tests to reduce the number of men who die from the disease.”
Research has also already led to an improvement in the way bowel cancer is diagnosed and prevented. A 16-year Cancer Research UK trial which showed how a one-off flexi-scope test* could reduce the number of deaths from bowel cancer by almost half (43 per cent), and the number of new cases by a third, in those who take up the screening test.
Professor Wendy Atkin, Cancer Research UK’s bowel cancer screening expert who led the research on flexi-scope screening, said: “Our research showed for the first time that we could dramatically reduce the incidence of bowel cancer, and the number of people dying from the disease, by using this one-off test.
“Our work is a fantastic example of the benefits that research can bring. There is no other way we would be able to develop new treatments, know whether a new treatment is better or worse and know who should receive it.”
Work by Cancer Research UK and others around the world has led to a number of promising new treatments for advanced melanoma that are bringing hope to patients. It is also critical to continue efforts to prevent the disease, as most cases are caused by too much exposure to ultraviolet (UV) radiation from the sun and sunbeds.
Dr Harpal Kumar, Cancer Research UK’s chief executive, said: “These figures provide a glimpse into the future. On the plus side our life expectancy is increasing but this also means more of us are likely to be diagnosed with cancer.
“It’s only through research that we will be able to beat cancer. We need to do more work to understand what drives cancer and how we can prevent it, as well as developing new treatments to reduce the number of people who will die from it.
“Understanding the biology of cancer is rather like completing a complex jigsaw puzzle. Many pieces have already fallen into place but we need more research before we can complete the picture. And thanks to the generosity of the public, our world class scientists are playing a leading role in beating this devastating disease.”
Recent AEMD News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2024 08:44:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 09:00:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 09:30:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 12:01:08 PM
- Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India • PR Newswire (US) • 09/19/2024 12:01:00 PM
- Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial • PR Newswire (US) • 09/16/2024 12:01:00 PM
- Aethlon Medical to Present at the Life Sciences Investor Forum September 19th • GlobeNewswire Inc. • 09/13/2024 12:35:00 PM
- Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys • PR Newswire (US) • 08/27/2024 12:01:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2024 08:34:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/15/2024 08:32:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/15/2024 08:30:33 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 08/15/2024 08:15:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:10:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:15:21 PM
- Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update • PR Newswire (US) • 08/14/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:01:08 PM
- Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 08/12/2024 12:01:00 PM
- Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024 • PR Newswire (US) • 08/06/2024 01:12:00 PM
- Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update • PR Newswire (US) • 06/27/2024 08:15:00 PM
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024 • PR Newswire (US) • 06/21/2024 12:01:00 PM
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 06/18/2024 12:01:00 PM
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies • PR Newswire (US) • 06/03/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 05:24:31 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM